,i #aaith ,,congress #b;d ,session ,h4 ,r4 #ajafd ,,in ,,the ,,house ,,of ,,representatives ,august #bg1 #bjbf,mr4 ,latta 7for himself and ,mrs4 ,dingell7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to direct the ,secretary of ,commerce to promote competitiveness in biomanufacturing in the ,united ,states1 identify supply-chain and commercialization vulnerabilities relating to critical biomanufacturing inputs and domestic production capacity1 improve transparency regarding ,federal processes applicable to biomanufactured products1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,biomanufacturing ,excellence1 ,domestic ,resilience1 ,output1 and ,competitive ,know-how ,act or the ,,bedrock ,act4 #b4 ,activities related to promoting competitiveness in biomanufacturing in the ,united ,states 7a7 ,in general ,not later than #a year after the date of the enactment of this ,act1 the ,secretary shall designate a senior official to-- 7#a7 lead the activities of the ,department of ,commerce relating to biomanufacturing and biomanufactured products in the ,united ,states2 7#b7 carry out the activities described in subsection 7b72 and 7#c7 promote commercial competitiveness with respect to such biomanufacturing and biomanufactured products4 7b7 ,activities described ,the activities described in this subsection are the following3 7#a7 ,identify the following3 7,a7 ,any ,federal process1 resource1 or publicly available information relevant to promoting commercial competitiveness with respect to biomanufacturing and biomanufactured products in domestic and foreign commerce4 7,b7 ,any barrier to private sector investment in biomanufacturing1 market adoption of biomanufactured products1 or domestic production of such products1 including barriers arising from unclear1 duplicative1 or unpredictable ,federal processes related to the commercialization of such products4 7,c7 ,any vulnerability1 chokepoint1 supplier concentration1 single point of failure1 market barrier1 or other constraint affecting a supply chain related to a critical biomanufacturing input1 including any such vulnerability1 chokepoint1 supplier concentration1 single point of failure1 market barrier1 or other constraint related to a foreign adversary or a foreign adversary entity4 7,d7 ,any opportunity for a private sector entity or policymaker to strengthen domestic production1 supplier diversification1 commercialization1 and supply chain resilience related to biomanufacturing or biomanufactured products4 7,e7 ,the availability of domestic production capacity1 inputs1 equipment1 and other resources related to the commercial manufacturing of biomanufactured products in the ,united ,states1 including with respect to the following3 7i7 ,amino acids4 7ii7 ,industrial enzymes4 7iii7 ,microbial strains4 7iv7 ,cell lines4 7v7 ,cell banks4 7vi7 ,bioreactors4 7vii7 ,single-use bioprocessing components4 7#b7 ,facilitate consultations1 on a voluntary basis1 for participating non-,federal entities to promote commercial competitiveness with respect to biomanufacturing and biomanufactured products1 including consultations required pursuant to subsection 7d77#c74 7#c7 ,consult with the heads of relevant ,federal agencies1 and any relevant agency point of contact1 including the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 and the ,administrator of the ,environmental ,protection ,agency1 as the ,secretary determines appropriate1 with respect to matters affecting the competitiveness of biomanufacturing1 supply-chain resilience1 and the commercial manufacturing of biomanufactured products4 7#d7 ,maintain a publicly available web resource that consolidates or provides links to publicly available ,federal resources relevant to the commercialization of biomanufactured products1 as determined appropriate by the ,secretary1 including the following information and resources3 7,a7 ,any practice identified and made publicly available under subsection 7d74 7,b7 ,the report required under subsection 7e77#a74 7,c7 ,any point of contact designated under subsection 7e77#c7 or otherwise made publicly available by a relevant ,federal agency4 7#e7 ,serve as a point of coordination for non-,federal entities seeking publicly available information related to a ,federal process identified under paragraph 7#a77;,a71 including by referring such entities to the appropriate ,federal agency or point of contact4 7c7 ,assessment 7#a7 ,in general ,not later than #a year after the date of the enactment of this ,act1 and every #b years thereafter1 the ,secretary1 acting through the senior official designated pursuant to subsection 7a71 shall conduct an assessment with respect to the following3 7,a7 ,the current and1 to the extent practicable1 reasonably foreseeable future availability of critical biomanufacturing inputs and domestic production capacity related to biomanufacturing in the ,united ,states4 7,b7 ,the extent to which private sector entities in the ,united ,states rely on foreign adversaries or foreign adversary entities for critical biomanufacturing inputs or production capacity related to biomanufacturing4 7,c7 ,any vulnerability1 chokepoint1 single point of failure1 supplier concentration1 market barrier1 or other constraint impacting the access of a private sector entity to critical biomanufacturing inputs or domestic production capacity related to biomanufacturing4 7,d7 ,the availability of substitutes for critical biomanufacturing inputs in the ,united ,states1 including from other sources that are not foreign adversaries or foreign adversary entities4 7,e7 ,estimated lead times and economic or operational barriers to reducing reliance by private sector entities on a foreign adversary or a foreign adversary entity for critical biomanufacturing inputs or production capacity related to biomanufacturing4 7,f7 ,any barrier identified under subsection 7b77#a77;,b71 including the following3 7i7 ,any ,federal process for which a review related to commercialization is divided among multiple ,federal agencies4 7ii7 ,any barrier arising from limited access to shared pilot-scale and demonstration-scale manufacturing capacity4 7,g7 ,any opportunity for domestic producers and suppliers to expand the capacity of1 improve the reliability of1 and diversify supply chains for critical biomanufacturing inputs4 7,h7 ,any impact on commerce and biomanufacturing in the ,united ,states if a vulnerability1 chokepoint1 single point of failure1 supplier concentration1 market barrier1 or other constraint identified under subparagraph 7,c7 is not addressed1 including any impact on relevant domestic supply-chain resilience and access to biomanufactured products4 7,i7 ,biomanufacturing capacity located outside of the ,united ,states1 including capacity at contract manufacturing facilities and company-owned facilities1 and capacity owned or controlled by foreign adversaries or foreign adversary entities1 to-- 7i7 compare such biomanufacturing capacity with the biomanufacturing capacity of the ,united ,states2 and 7ii7 assess the impact of such capacity on domestic industry4 7#b7 ,prioritization ,in conducting the assessment under paragraph 7#a71 the ,secretary1 acting through the senior official designated pursuant to subsection 7a71 shall prioritize the matters described in such paragraph based on the following3 7,a7 ,the commercial significance of the relevant affected critical biomanufacturing input or production capacity4 7,b7 ,potential consequences for commerce in the ,united ,states4 7,c7 ,the extent of reliance on foreign adversaries or foreign adversary entities4 7,d7 ,estimated lead times and barriers to reducing such reliance4 7,e7 ,the availability of substitute sources4 7#c7 ,prioritized action plan ,based on each assessment under paragraph 7#a71 the ,secretary shall prepare and include in any report submitted and made publicly available under subsection 7g7 a prioritized action plan that-- 7,a7 ranks each supply-chain risk and commercialization barrier identified in the assessment by commercial significance and potential consequence for commerce in the ,united ,states2 7,b7 identifies actions the ,secretary may take to improve supply-chain visibility1 stakeholder coordination1 and access to information related to the commercialization of biomanufactured products2 7,c7 identifies existing ,federal financial assistance programs and other ,federal resources that may address any such supply-chain risk or commercialization barrier2 7,d7 identifies any program or resource described in subparagraph 7,c7 that should be added to the web resource maintained under subsection 7b77#d72 and 7,e7 identifies opportunities for the ,secretary to coordinate with relevant ,federal agencies and non-,federal entities to reduce such risks and barriers4 7d7 ,voluntary practices 7#a7 ,in general ,not later than #a year after the date of the enactment of this ,act1 and as the ,secretary determines appropriate thereafter1 the ,secretary shall identify and make publicly available industry-led1 evidence-based1 or widely accepted practices related to the following3 7,a7 ,the commercialization of biomanufacturing processes and biomanufactured products4 7,b7 ,the readiness of biomanufacturing processes or biomanufactured products for commercial production4 7,c7 ,the reliability and operational consistency of biomanufacturing processes and the quality of biomanufactured products4 7,d7 ,supplier qualification1 supplier diversification1 and commercial supply chain risk management for critical biomanufacturing inputs4 7,e7 ,the voluntary sharing of nonproprietary information related to biomanufacturing process and the supply chains for biomanufacturing processes or biomanufactured products that is necessary to support commercialization and commercial manufacturing1 including the secure and portable transfer of information that a process originator elects to share with a manufacturing partner1 as appropriate4 7,f7 ,the protection of trade secrets1 confidential business information1 and intellectual property relating to biomanufacturing4 7,g7 ,the participation of small and medium-sized businesses and manufacturers in biomanufacturing4 7,h7 ,the use of biomanufactured products in domestic and foreign commerce4 7,i7 ,the use of digital1 computational1 automated1 or artificial intelligence tools in commercial biomanufacturing to improve reliability1 efficiency1 product quality1 and consistency4 7#b7 ,existing practices ,in carrying out paragraph 7#a71 the ,secretary shall-- 7,a7 prioritize identifying existing practices1 including practices issued or maintained by industry-led organizations1 and making such practices publicly available2 and 7,b7 avoid unnecessary duplication of such practices4 7#c7 ,consultation ,in carrying out paragraph 7#a71 the ,secretary shall consult with non-,federal entities1 including the following3 7,a7 ,the following private sector entities3 7i7 ,manufacturers and suppliers of critical biomanufacturing inputs4 7ii7 ,small and medium-sized businesses and manufacturers of biomanufactured products4 7iii7 ,companies seeking to commercialize1 produce1 or use biomanufactured products4 7iv7 ,investors1 accelerators1 and other entities involved in commercialization4 7,b7 ,state1 local1 ,tribal1 territorial1 and regional commerce or manufacturing organizations4 7,c7 ,experts in commercial supply-chain resilience1 manufacturing1 and competitiveness4 7#d7 ,prioritization of ,united ,states and trusted stakeholders ,in carrying out paragraph 7#c71 the ,secretary shall prioritize1 to the extent practicable1 input from non-,federal entities in the ,united ,states and other stakeholders that are neither foreign adversaries nor foreign adversary entities4 7#e7 ,public input 7,a7 ,in general ,the ,secretary shall provide at least #a opportunity for the public to submit input under this subsection4 7,b7 ,methods ,the ,secretary may solicit public input under this subsection through making requests for information1 workshops1 roundtables1 meetings with non-,federal entities1 or any other means the ,secretary determines appropriate4 7e7 ,federal commercialization pathway map2 agency points of contact 7#a7 ,report ,not later than #a year after the date of the enactment of this ,act1 the ,secretary1 in consultation with the heads of relevant ,federal agencies1 shall submit to the appropriate congressional committees and make publicly available a report that identifies and maps any ,federal process that may apply to the commercialization of biomanufactured products and critical biomanufacturing inputs1 as the ,secretary determines appropriate4 7#b7 ,contents ,the report required under paragraph 7#a7 shall do the following3 7,a7 ,organize any ,federal process identified and mapped under such paragraph by category of biomanufactured product or critical biomanufacturing input1 as the ,secretary determines appropriate4 7,b7 ,identify the following3 7i7 ,any publicly available point of contact for a ,federal agency and any existing public guidance related to any such ,federal process4 7ii7 ,overlaps1 gaps1 ambiguities1 and timing or predictability concerns related to any such ,federal process4 7iii7 ,opportunities to improve the clarity and predictability of1 and reduce duplication among1 any such ,federal process4 7#c7 ,agency points of contact ,not later than #ahj days after the date of the enactment of this ,act-- 7,a7 the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 shall-- 7i7 designate a point of contact to assist non-,federal entities in identifying publicly available information related to any process of the ,food and ,drug ,administration that may apply to biomanufactured products or critical biomanufacturing inputs2 and 7ii7 ensure such point of contact coordinates1 as appropriate1 with relevant components of the ,food and ,drug ,administration in carrying out clause 7i72 and 7,b7 the ,administrator of the ,environmental ,protection ,agency shall designate a point of contact to assist non-,federal entities in identifying publicly available information related to laws administered by the ,administrator of the ,environmental ,protection ,agency that may apply to biomanufactured products or critical biomanufacturing inputs4 7#d7 ,integration with existing resources 7,a7 ,in general ,in carrying out paragraphs 7#a7 and 7#b71 the ,secretary may incorporate or rely on a substantially similar existing ,federal resource1 report1 assessment1 map1 or other activity if the ,secretary determines that it substantially addresses the applicable requirement4 7,b7 ,inclusion in report ,if the ,secretary incorporates or relies on a substantially similar existing ,federal resource1 report1 assessment1 map1 or other activity under subparagraph 7,a71 the ,secretary shall include in the report required under paragraph 7#a7 the following3 7i7 ,an identification of the resource1 report1 assessment1 map1 or other activity4 7ii7 ,an explanation of how the resource1 report1 assessment1 map1 or other activity addresses the applicable requirement4 7#e7 ,updates ,the ,secretary shall update the report required under paragraph 7#a7 to reflect any material change to any ,federal process described in such paragraph1 as the ,secretary determines appropriate4 7f7 ,protection of information 7#a7 ,in general ,the ,secretary may not publicly disclose any nonpublic information voluntarily submitted by a non-,federal entity under this section that-- 7,a7 constitutes a trade secret or confidential business information2 or 7,b7 is sensitive supply-chain vulnerability information4 7#b7 ,exemption from disclosure ,information described in paragraph 7#a7 shall be exempt from disclosure under section #eeb7;b77#c7 of title #e1 ,united ,states ,code4 7#c7 ,identification and determination 7,a7 ,in general ,the ,secretary shall establish a process for a non-,federal entity that voluntarily submits information under this section to identify whether the entity considers such information to be nonpublic information described in paragraph 7#a74 7,b7 ,determination ,if a non-,federal entity makes an identification under the process required by subparagraph 7,a71 with respect to information voluntarily submitted under this section by such entity1 the ,secretary shall determine whether such information is nonpublic information described in paragraph 7#a74 7,c7 ,treatment pending determination ,the ,secretary may not publicly disclose any information with respect to which a non-,federal entity makes an identification under paragraph 7#c77;,a7 unless the ,secretary has determined such information is not nonpublic information described in paragraph 7#a74 7g7 ,reports 7#a7 ,in general ,not later than #a year after the date of the enactment of this ,act1 and every #b years thereafter1 the ,secretary1 acting through the senior official designated pursuant to subsection 7a71 shall submit to the appropriate congressional committees1 and make publicly available on a website of the ,department of ,commerce1 a report that includes the following3 7,a7 ,a summary of any action carried out by the ,secretary under this section4 7,b7 ,any assessment conducted under subsection 7c74 7,c7 ,any prioritized action plan prepared under paragraph 7#c7 of such subsection4 7,d7 ,a summary of any practices identified and made publicly available under subsection 7d74 7,e7 ,any updates related to the report required under subsection 7e77#a74 7#b7 ,nonpublic annex ,the ,secretary1 acting through the senior official designated pursuant to subsection 7a71 may submit to the appropriate congressional committees a nonpublic annex to a report required under paragraph 7#a7 that includes nonpublic information described in subsection 7f77#a74 7h7 ,termination ,the requirements under subsections 7a7 through 7e7 and subsection 7g7 shall terminate on the date that is #e years after the date of the enactment of this ,act4 7i7 ,definitions ,in this section3 7#a7 ,appropriate congressional committees ,the term appropriate congressional committees means-- 7,a7 the ,committee on ,energy and ,commerce of the ,house of ,representatives2 and 7,b7 the ,committee on ,commerce1 ,science1 and ,transportation of the ,senate4 7#b7 ,biomanufactured product ,the term biomanufactured product means a commercial good1 material1 chemical1 protein1 component1 industrial input1 or other product or substance in commerce that is produced1 processed1 purified1 or transformed through biomanufacturing4 7#c7 ,biomanufacturing ,the term biomanufacturing means the use of biological systems1 including cells1 cell-free systems1 enzymes1 or biomolecules1 in manufacturing processes to produce1 process1 or transform commercial goods1 materials1 chemicals1 proteins1 components1 industrial inputs1 or other products or substances in commerce4 7#d7 ,critical biomanufacturing input ,the term critical biomanufacturing input means an input1 material1 reagent1 item of equipment1 or software used in biomanufacturing that is commercially significant to biomanufacturing in the ,united ,states and subject to supply-chain risk1 such as supplier concentration1 reliance on a foreign adversary or foreign adversary entity1 limited substitutes1 or long lead times4 7#e7 ,foreign adversary ,the term foreign adversary means a foreign government or foreign non-government person identified as a foreign adversary under section #gia4d of title #ae1 ,code of ,federal ,regulations1 or any successor regulation4 7#f7 ,foreign adversary entity ,the term foreign adversary entity has the meaning given the term person owned by1 controlled by1 or subject to the jurisdiction or direction of a foreign adversary in section #gia4b of title #ae1 ,code of ,federal ,regulations1 or any successor regulation4 7#g7 ,non-federal entity ,the term non-,federal entity means a ,state1 local1 ,tribal1 or territorial government1 nonprofit organization1 technical organization1 industry association1 commerce or manufacturing organization1 private sector entity1 or other stakeholder4 7#h7 ,secretary ,the term ,secretary means the ,secretary of ,commerce4 7#i7 ,sensitive supply-chain vulnerability information ,the term sensitive supply-chain vulnerability information means nonpublic information with respect to which the public disclosure of such nonpublic information could be reasonably expected to reveal a vulnerability1 dependency1 chokepoint1 single point of failure1 supplier concentration1 or other weakness in a supply chain relevant to biomanufacturing in the ,united ,states4